[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Allurion Technologies Inc (ALUR)

Allurion Technologies Inc (ALUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 10,110
  • Shares Outstanding, K 14,994
  • Annual Sales, $ 15,230 K
  • Annual Income, $ -28,760 K
  • EBIT $ -30 M
  • EBITDA $ -29 M
  • 60-Month Beta -0.22
  • Price/Sales 0.73
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.32
  • Most Recent Earnings $-1.18 on 11/12/25
  • Next Earnings Date 05/13/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Products

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $0.43
  • Growth Rate Est. (year over year) +232,225.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6201 +8.74%
on 04/28/26
0.9800 -31.19%
on 04/10/26
-0.0158 (-2.29%)
since 03/30/26
3-Month
0.2300 +193.17%
on 03/10/26
2.0699 -67.42%
on 02/23/26
-0.6757 (-50.05%)
since 01/30/26
52-Week
0.2300 +193.17%
on 03/10/26
3.4200 -80.28%
on 05/14/25
-1.6957 (-71.55%)
since 04/30/25

Most Recent Stories

More News
Allurion Treats First Commercial Patients in the United States, Marking Major Milestone

Allurion Technologies, Inc. (OTCID: ALUR), a pioneer in metabolically healthy weight loss, today announced the successful commercial treatment of its first patients in the United States—an inflection...

ALUR : 0.6743 (-8.88%)
Allurion Advances Plan to Regain Listing Compliance

Files appeal to NYSE on decision to initiate delisting proceedings Company’s recent FDA approval catalyzes plan to regain compliance with the continued listing requirements...

ALUR : 0.6743 (-8.88%)
Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy

First shipments expected in April

ALUR : 0.6743 (-8.88%)
Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE

Company’s recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process...

ALUR : 0.6743 (-8.88%)
Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds

Allurion Technologies, Inc. (NYSE: ALUR) (the “Company” or “Allurion”), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise...

ALUR : 0.6743 (-8.88%)
Allurion Receives U.S. FDA Approval

Approval provides Allurion with access to approximately 80 million Americans with obesity

ALUR : 0.6743 (-8.88%)
Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices

Through Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule

ALUR : 0.6743 (-8.88%)
Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Strong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss

ALUR : 0.6743 (-8.88%)
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence

Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months All patients remained adherent to tirzepatide for the duration of the study

ALUR : 0.6743 (-8.88%)
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone

Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle...

ALUR : 0.6743 (-8.88%)

Business Summary

Allurion Technologies Inc. is dedicated to ending obesity. The Allurion Program is a weight loss platform which combines the Allurion Gastric Balloon and only swallowable, procedure-less gastric balloon for weight loss, the Allurion Virtual Care Suite including the Allurion Mobile App for consumers,...

See More

Key Turning Points

3rd Resistance Point 0.8838
2nd Resistance Point 0.8419
1st Resistance Point 0.7581
Last Price 0.6743
1st Support Level 0.6324
2nd Support Level 0.5905
3rd Support Level 0.5067

See More

52-Week High 3.4200
Fibonacci 61.8% 2.2014
Fibonacci 50% 1.8250
Fibonacci 38.2% 1.4486
Last Price 0.6743
52-Week Low 0.2300

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.